Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578316 | 0.82 | TSHR (0.50) | CHRM3CHRM2CHRM1CYP2D6BCHE | |
| SCHEMBL6578254 | 0.80 | CHRM2 (0.52) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL6574095 | 0.76 | CHRM2 (0.50) | CHRM3CHRM2CHRM1CYP2D6CHRM4 | |
| SCHEMBL231643 | 0.73 | CHRM3 (0.47) | CHRM3CHRM2CHRM1CYP2D6CHRM4 | |
| SCHEMBL6574169 | 0.70 | CHRM2 (0.50) | CHRM3CHRM2CHRM1CYP2D6CHRM4 | |
| SCHEMBL16956227 | 0.65 | CYP4F2 (0.54) | CYP2D6CYP4F2CYP4A11 | |
| SCHEMBL9359858 | 0.65 | CYP4F2 (0.54) | CYP2D6CYP4F2CYP4A11 | |
| SCHEMBL228830 | 0.65 | CHRM2 (0.54) | CHRM3CHRM2CHRM1CYP2D6CHRM4 | |
| SCHEMBL6340138 | 0.64 | LOXL2 (0.54) | CYP4F2CYP4A11 | |
| SCHEMBL28523575 | 0.64 | LOXL2 (0.54) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | claimed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | claimed |
| EP-1383730-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | Aryx Therapeutics (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002096855-A2 | ANTICHOLINERGIC COMPOUNDS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | ARYX THERAPEUTICS | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169208-A1 | Novel anticholinergic compounds and methods of use | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.